NOVO NORDISK A/S-B (NOV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:NOV - DK0062498333 - Common Stock
51.05 EUR
+0.33 (+0.65%)
Overall NOV gets a fundamental rating of 6 out of 10. We evaluated NOV against 53 industry peers in the Pharmaceuticals industry. While NOV belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. NOV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year NOV was profitable.
NOV had a positive operating cash flow in the past year.
Each year in the past 5 years NOV has been profitable.
In the past 5 years NOV always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.26%, NOV belongs to the top of the industry, outperforming 98.11% of the companies in the same industry.
NOV has a Return On Equity of 61.08%. This is amongst the best in the industry. NOV outperforms 94.34% of its industry peers.
NOV's Return On Invested Capital of 38.03% is amongst the best of the industry. NOV outperforms 98.11% of its industry peers.
NOV had an Average Return On Invested Capital over the past 3 years of 50.29%. This is significantly above the industry average of 14.02%.
The last Return On Invested Capital (38.03%) for NOV is well below the 3 year average (50.29%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| ROIC | 38.03% |
ROA(3y)23.77%
ROA(5y)24.99%
ROE(3y)71.81%
ROE(5y)69.89%
ROIC(3y)50.29%
ROIC(5y)49.64%
1.3 Margins
NOV's Profit Margin of 32.88% is amongst the best of the industry. NOV outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of NOV has grown nicely.
The Operating Margin of NOV (42.03%) is better than 94.34% of its industry peers.
In the last couple of years the Operating Margin of NOV has grown nicely.
With an excellent Gross Margin value of 82.05%, NOV belongs to the best of the industry, outperforming 84.91% of the companies in the same industry.
NOV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.03% | ||
| PM (TTM) | 32.88% | ||
| GM | 82.05% |
OM growth 3Y4.3%
OM growth 5Y1.69%
PM growth 3Y0.84%
PM growth 5Y1.73%
GM growth 3Y0.72%
GM growth 5Y0.24%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NOV is creating value.
Compared to 1 year ago, NOV has less shares outstanding
The number of shares outstanding for NOV has been increased compared to 5 years ago.
NOV has a worse debt/assets ratio than last year.
2.2 Solvency
NOV has an Altman-Z score of 4.76. This indicates that NOV is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.76, NOV is doing good in the industry, outperforming 69.81% of the companies in the same industry.
NOV has a debt to FCF ratio of 1.66. This is a very positive value and a sign of high solvency as it would only need 1.66 years to pay back of all of its debts.
NOV has a Debt to FCF ratio of 1.66. This is amongst the best in the industry. NOV outperforms 88.68% of its industry peers.
NOV has a Debt/Equity ratio of 0.52. This is a neutral value indicating NOV is somewhat dependend on debt financing.
NOV has a Debt to Equity ratio of 0.52. This is in the better half of the industry: NOV outperforms 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 1.66 | ||
| Altman-Z | 4.76 |
ROIC/WACC6.21
WACC6.12%
2.3 Liquidity
A Current Ratio of 0.78 indicates that NOV may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.78, NOV is doing worse than 84.91% of the companies in the same industry.
A Quick Ratio of 0.57 indicates that NOV may have some problems paying its short term obligations.
NOV has a Quick ratio of 0.57. This is in the lower half of the industry: NOV underperforms 79.25% of its industry peers.
NOV does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.05% over the past year.
NOV shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.54% yearly.
The Revenue has grown by 16.64% in the past year. This is quite good.
Measured over the past years, NOV shows a quite strong growth in Revenue. The Revenue has been growing by 18.94% on average per year.
EPS 1Y (TTM)10.05%
EPS 3Y29.71%
EPS 5Y22.54%
EPS Q2Q%-26.47%
Revenue 1Y (TTM)16.64%
Revenue growth 3Y27.29%
Revenue growth 5Y18.94%
Sales Q2Q%5.14%
3.2 Future
Based on estimates for the next years, NOV will show a small growth in Earnings Per Share. The EPS will grow by 5.49% on average per year.
NOV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.10% yearly.
EPS Next Y4.79%
EPS Next 2Y0.88%
EPS Next 3Y2.8%
EPS Next 5Y5.49%
Revenue Next Year7.98%
Revenue Next 2Y4.04%
Revenue Next 3Y4.95%
Revenue Next 5Y6.1%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.36 indicates a correct valuation of NOV.
Compared to the rest of the industry, the Price/Earnings ratio of NOV indicates a somewhat cheap valuation: NOV is cheaper than 69.81% of the companies listed in the same industry.
NOV's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.25.
The Price/Forward Earnings ratio is 16.56, which indicates a correct valuation of NOV.
NOV's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NOV is cheaper than 64.15% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, NOV is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.36 | ||
| Fwd PE | 16.56 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NOV is valued a bit cheaper than 62.26% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as NOV.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.81 | ||
| EV/EBITDA | 11.36 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of NOV may justify a higher PE ratio.
PEG (NY)3.42
PEG (5Y)0.73
EPS Next 2Y0.88%
EPS Next 3Y2.8%
5. Dividend
5.1 Amount
No dividends for NOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:NOV (1/12/2026, 7:00:00 PM)
51.05
+0.33 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners33.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap226.84B
Revenue(TTM)315.60B
Net Income(TTM)103.77B
Analysts71.88
Price Target54.95 (7.64%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend1.33
Dividend Growth(5Y)16.56%
DP49.88%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.09%
Min EPS beat(2)-7.04%
Max EPS beat(2)-1.15%
EPS beat(4)2
Avg EPS beat(4)0.81%
Min EPS beat(4)-7.04%
Max EPS beat(4)7.46%
EPS beat(8)5
Avg EPS beat(8)1.75%
EPS beat(12)8
Avg EPS beat(12)1.59%
EPS beat(16)11
Avg EPS beat(16)1.6%
Revenue beat(2)0
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)0.55%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)6.95%
Revenue beat(8)3
Avg Revenue beat(8)0.61%
Revenue beat(12)6
Avg Revenue beat(12)0.51%
Revenue beat(16)9
Avg Revenue beat(16)0.77%
PT rev (1m)-1.84%
PT rev (3m)-15.31%
EPS NQ rev (1m)-1.77%
EPS NQ rev (3m)-9.84%
EPS NY rev (1m)-0.49%
EPS NY rev (3m)-4.03%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-8.7%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-2.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.36 | ||
| Fwd PE | 16.56 | ||
| P/S | 5.37 | ||
| P/FCF | 27.81 | ||
| P/OCF | 13.69 | ||
| P/B | 9.98 | ||
| P/tB | 26.77 | ||
| EV/EBITDA | 11.36 |
EPS(TTM)3.12
EY6.11%
EPS(NY)3.08
Fwd EY6.04%
FCF(TTM)1.84
FCFY3.6%
OCF(TTM)3.73
OCFY7.3%
SpS9.51
BVpS5.12
TBVpS1.91
PEG (NY)3.42
PEG (5Y)0.73
Graham Number18.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| ROCE | 47.73% | ||
| ROIC | 38.03% | ||
| ROICexc | 43.08% | ||
| ROICexgc | 76.17% | ||
| OM | 42.03% | ||
| PM (TTM) | 32.88% | ||
| GM | 82.05% | ||
| FCFM | 19.31% |
ROA(3y)23.77%
ROA(5y)24.99%
ROE(3y)71.81%
ROE(5y)69.89%
ROIC(3y)50.29%
ROIC(5y)49.64%
ROICexc(3y)60.7%
ROICexc(5y)59.32%
ROICexgc(3y)124.92%
ROICexgc(5y)112.44%
ROCE(3y)63.71%
ROCE(5y)65.35%
ROICexgc growth 3Y-1.28%
ROICexgc growth 5Y0.46%
ROICexc growth 3Y-2.16%
ROICexc growth 5Y-9.95%
OM growth 3Y4.3%
OM growth 5Y1.69%
PM growth 3Y0.84%
PM growth 5Y1.73%
GM growth 3Y0.72%
GM growth 5Y0.24%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 1.66 | ||
| Debt/EBITDA | 0.58 | ||
| Cap/Depr | 290.66% | ||
| Cap/Sales | 19.91% | ||
| Interest Coverage | 53.02 | ||
| Cash Conversion | 80.23% | ||
| Profit Quality | 58.73% | ||
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 4.76 |
F-Score4
WACC6.12%
ROIC/WACC6.21
Cap/Depr(3y)294.05%
Cap/Depr(5y)277.71%
Cap/Sales(3y)14.25%
Cap/Sales(5y)13.08%
Profit Quality(3y)89.38%
Profit Quality(5y)87.75%
High Growth Momentum
Growth
EPS 1Y (TTM)10.05%
EPS 3Y29.71%
EPS 5Y22.54%
EPS Q2Q%-26.47%
EPS Next Y4.79%
EPS Next 2Y0.88%
EPS Next 3Y2.8%
EPS Next 5Y5.49%
Revenue 1Y (TTM)16.64%
Revenue growth 3Y27.29%
Revenue growth 5Y18.94%
Sales Q2Q%5.14%
Revenue Next Year7.98%
Revenue Next 2Y4.04%
Revenue Next 3Y4.95%
Revenue Next 5Y6.1%
EBIT growth 1Y6.92%
EBIT growth 3Y32.76%
EBIT growth 5Y20.94%
EBIT Next Year18.56%
EBIT Next 3Y8.09%
EBIT Next 5Y8.99%
FCF growth 1Y-21.68%
FCF growth 3Y13.52%
FCF growth 5Y14.4%
OCF growth 1Y16.27%
OCF growth 3Y30.05%
OCF growth 5Y20.93%
NOVO NORDISK A/S-B / NOV.DE FAQ
What is the fundamental rating for NOV stock?
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.
Can you provide the valuation status for NOVO NORDISK A/S-B?
ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.
What is the profitability of NOV stock?
NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for NOV stock?
The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to grow by 4.79% in the next year.
Is the dividend of NOVO NORDISK A/S-B sustainable?
The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 0 / 10 and the dividend payout ratio is 49.88%.